论文部分内容阅读
目的:贝伐珠单抗是血管内皮生长因子的重组人源化单克隆IgGl抗体,通过抑制肿瘤血管生成而发挥抗肿瘤作用。本研究旨在观察贝伐珠单抗联合化学药物治疗晚期胃癌的疗效与安全性。方法:12例晚期胃癌患者均经病理组织学确诊后接受贝伐珠单抗联合化学药物治疗。贝伐珠单抗的剂量为7.5 mg/kg,第1天给药,21 d 1个周期,每2个周期评价疗效。结果:12例患者均可评价疗效和毒副反应,一线治疗5例,二线治疗7例,根据实体瘤的疗效(response evaluation criteria insolid tumors,RECIST)评定标准,无完全缓解患者,部分缓解8例(66.7%),病情稳定3例(25.0%),病情进展1例(8.3%),客观有效率67%,疾病控制率91%。中位无进展生存时间5.5个月,中位总生存期7.0个月。骨髓抑制6例,肝损害3例,胃肠道反应2例,高血压1例,均为I~II度,经对症治疗后好转,无严重不良事件。结论:贝伐珠单抗联合化学药物治疗晚期胃癌临床疗效较好,用药期间不良反应可耐受。
OBJECTIVE: Bevacizumab is a recombinant humanized monoclonal IgGl antibody against vascular endothelial growth factor and exerts anti-tumor effects by inhibiting tumor angiogenesis. This study was designed to observe the efficacy and safety of bevacizumab combined with chemotherapy in the treatment of advanced gastric cancer. Methods: Twelve patients with advanced gastric cancer were diagnosed by histopathology and treated with bevacizumab combined with chemical drugs. Bevacizumab was administered at a dose of 7.5 mg / kg administered on day 1 for 21 days and evaluated every 2 cycles. Results: Efficacy and adverse reactions were evaluated in 12 patients. The first-line treatment was in 5 cases and the second-line treatment in 7 cases. According to RECIST criteria, there was no complete remission in 8 patients (66.7%), stable disease in 3 cases (25.0%), progression of disease in 1 case (8.3%), objective efficiency of 67% and disease control rate of 91%. The median progression-free survival time was 5.5 months, with a median overall survival of 7.0 months. Myelosuppression in 6 cases, liver damage in 3 cases, 2 cases of gastrointestinal reactions, hypertension in 1 case, were I ~ II degrees, improved after symptomatic treatment, no serious adverse events. Conclusion: Bevacizumab combined with chemotherapeutic drugs in the treatment of advanced gastric cancer has better curative effect and adverse reactions can be tolerated during the treatment.